[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
We report 2 patients with metastatic ovarian tumors of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection, and showed a relatively good outcome. Case 1 A 40-year-old female with gastric cancer located in the MULE area underwent total gastrectomy with D3 lymph node dissection on June 2, 1989. Pathological Stage was IIIB and curability was B according to the JGCA classification. In month 56 after surgery, a left ovarian tumor was detected, and bilateral oophorectomy with paraaortic and intrapelvic lymph node dissection was performed. Signet ring cell carcinoma from the stomach was confirmed in both left ovary and lymph node around the left external iliac artery. In month 51 after the oophorectomy, the patient died from carcinomatous peritonitis. Case 2 A 23-year-old female with gastric cancer located in the M area underwent distal gastrectomy with D3 lymph node dissection on November 1, 2000. Pathological Stage was IV and curability was B according to the JGCA classification. In month 19 after surgery, a left ovarian tumor was detected, and left oophorectomy with paraaortic and intrapelvic lymph node dissection was performed. Poorly differentiated adenocarcinoma from the stomach was confirmed in both left ovary and paraaortic lymph nodes. Chemoradiation therapy was performed for the bone metastasis in lumbar vertebra, which was detected in month 4 after the oophorectomy, and partial response was achieved. As of June 2003, no other malignant lesion has been detected.
Nishioka
Kiyonori
K
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Arai
Kuniyoshi
K
Iwasaki
Yoshiaki
Y
Katayanagi
Soh
S
Takahashi
Keiichi
K
Yamaguchi
Tatsuro
T
Matsumoto
Hiroshi
H
Miyamoto
Hidenori
H
Horiguchi
Shinichiro
S
D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001011:Aorta; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018279:Carcinoma, Signet Ring Cell / Q000556:secondary / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D000077146:Irinotecan; D007725:Krukenberg Tumor / Q000556:secondary / Q000601:surgery; D008197:Lymph Node Excision / Q000379:methods*; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D010051:Ovarian Neoplasms / Q000556:secondary* / Q000601:surgery*; D010052:Ovariectomy; D013274:Stomach Neoplasms / Q000473:pathology*
D000077146:Irinotecan; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin